ZYME (NASDAQ: ZYME) insider files Form 144 to sell 6,832 shares

Rhea-AI Filing Summary

ZYME filed a notice of proposed sale of restricted securities under Rule 144. The notice covers the planned sale of 6,832 shares of common stock through Morgan Stanley Wealth Management Canada on or about 01/12/2026 on the Nasdaq market, with an aggregate market value of 158,297.44 at the time of the notice. The filing states that 17,666 shares of common stock were acquired on 01/12/2026 through the vesting of restricted stock units awarded by the issuer. The notice also indicates that 74,836,534 shares of common stock were outstanding at the time referenced.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Wealth Management Canada 140 4th Ave. SW, Suite 2740 Calgary A0 T2P 3N3	6832	158297.44	74836534	01/12/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/12/2026	Vesting of Restricted Stock Units	Issuer			17666	01/12/2026	Vesting of Award

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ZYME Form 144 filing disclose?

The Form 144 filing discloses a planned sale of 6,832 shares of ZYME common stock under Rule 144 through Morgan Stanley Wealth Management Canada on the Nasdaq market.

What is the aggregate market value of the ZYME shares to be sold?

The planned sale of 6,832 shares of ZYME common stock has an aggregate market value of 158,297.44 as stated in the notice.

How and when were the ZYME shares in the Form 144 acquired?

The filing states that 17,666 shares of ZYME common stock were acquired on 01/12/2026 through the vesting of restricted stock units granted by the issuer, described as a vesting of award.

How many ZYME shares were outstanding at the time referenced in the Form 144?

The Form 144 notes that there were 74,836,534 shares of ZYME common stock outstanding at the time referenced in the notice.

On which exchange will the ZYME shares in the Form 144 be sold?

The notice indicates that the 6,832 shares of ZYME common stock are intended to be sold on the Nasdaq exchange.

What does the representation in the ZYME Form 144 signature section mean?

By signing the notice, the person for whose account the ZYME securities are to be sold represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.